97 related articles for article (PubMed ID: 38467235)
21. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
24. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A
Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953
[TBL] [Abstract][Full Text] [Related]
26. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
27. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
28. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
Shah MP; Neal JW
Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
[TBL] [Abstract][Full Text] [Related]
29. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
30. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
31. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
32. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
33. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
34. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced
Solassol I; Pinguet F; Quantin X
Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671561
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive review of protein kinase inhibitors for cancer therapy.
Kannaiyan R; Mahadevan D
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1249-1270. PubMed ID: 30259761
[TBL] [Abstract][Full Text] [Related]
36. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
37. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
38. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
39. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
Johnson M; Garassino MC; Mok T; Mitsudomi T
Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
[TBL] [Abstract][Full Text] [Related]
40. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
